key: cord-0709894-ifnbq4ng
authors: Herstein, Jocelyn J; Lowe, John J; Wolf, Timo; Vasoo, Shawn; Leo, Yee Sin; Chin, BumSik; Shen, Yinzhong; Hewlett, Angela L; Lawler, James V
title: Leveraging a preexisting global infectious disease network for local decision-making during a pandemic
date: 2021-07-28
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab660
sha: 210ac71010da2caeb02607052a812f3dbcceafdc
doc_id: 709894
cord_uid: ifnbq4ng

Emerging infectious disease epidemics require a rapid response from health systems; however, evidence-based consensus guidelines are generally absent early in the course of events. Formed in 2017 by five high-level isolation units spanning three continents, the experience of the Global Infectious Disease Preparedness Network (GIDPN) early in the course of COVID-19 provides a model for accelerating best practice development and improving decision-making in health emergencies. The network served as a platform for real-time, open and transparent information-sharing during unknowns of an active outbreak by clinicians caring for patients, by researchers conducting clinical trials and transmission and infection prevention studies, and by teams advising local and national policymakers. Shared knowledge led to earlier adoption of some treatment modalities as compared to most peer institutions and to implementation of protocols prior to incorporation into national guidelines. GIDPN and similar networks are integral in enhancing preparedness for and response to future epidemics/pandemics.

M a n u s c r i p t 3

Emerging infectious disease epidemics require health systems to respond rapidly to reduce morbidity and mortality in the ill, prevent ongoing nosocomial and community transmission, and preserve the functional ability to deliver care; however, evidence-based consensus guidelines are generally absent early in the course of events. During the first wave of COVID-19 in the spring of 2020, hospitals' approaches to clinical management and infection prevention and control (IPC) practices varied widely, but as evidence and best practices accumulated, outcomes significantly improved over time [1] . Earlier elucidation of best practices could have markedly reduced the extent and impact of COVID-19 spread in the spring wave, and future preparedness approaches should focus on mechanisms for achieving that goal. The experience of the Global Infectious Disease Preparedness Network (GIDPN) early in the course of COVID-19 provides a model for accelerating best practice development and improving decision-making in health emergencies.

The emergence of high-consequence infectious diseases (HCIDs) (e.g., viral hemorrhagic fevers, Middle East Respiratory Syndrome [MERS] ) has increased in recent decades, potentially fueled by ecological and environmental factors and increased global fluidity of people and goods. A new infectious disease has emerged, on average, every year for the past 30 years [2] , while others have emerged in new geographic regions. Previous HCID outbreaks have underscored the occupational risks that healthcare workers assume when treating these patients, as they have exhibited significantly higher infection rates than the general population [3] [4] [5] [6] . As a result, special clinical units have been developed to mitigate nosocomial transmission and protect healthcare workers treating patients with these diseases. Termed "high-level isolation units (HLIU)", these facilities are equipped with extensively trained staff, biosecurity measures, robust standard operating procedures atypical of routine clinical settings, advanced engineering controls, and frameworks for rapidly conducting clinical research [7] .

A c c e p t e d M a n u s c r i p t 4 Globally, an increasing number of HLIUs have been established, either in response to previous regional HCID events or in anticipation of the next HCID threat. Five of these units, each representing core contributors to global health systems preparedness for HCIDs and each with firsthand experience caring for patients with HCIDs, partnered in 2017 to form the GIDPN. These 

In early 2020, when COVID-19 emerged in Wuhan, China, GIDPN members began sharing information and seeking technical advice from each other via email, as HLIUs readied to care for potential patients with the novel coronavirus. Beginning in early February, biweekly virtual meetings were scheduled to support rapid exchange of best practices, treatment modalities, concerns, and challenges that each HLIU was encountering. When science and knowledge were evolving daily, the network served as a platform for real-time open and transparent dialogue. This was conducted by clinicians caring for patients, by researchers conducting clinical trials and transmission and infection prevention studies, and by teams advising local and state/regional policymakers and decision-makers.

A c c e p t e d M a n u s c r i p t 6 Shared knowledge led to earlier adoption of some treatment modalities as compared to most peer institutions and to implementation of infection prevention protocols prior to incorporation into national guidelines. Here, we detail specific lessons learned and impacts of these conversations as they related to 1) early clinical and epidemiological observations, 2) therapeutics and rapid response clinical trials, 3) early transmission and infection prevention studies and protocols, and 4) diagnostics.

As COVID-19 impacted some member countries earlier than others, firsthand information from those institutions caring for patients with COVID-19 was invaluable, both clinically and epidemiologically. From the epidemiological standpoint, for example, the Nebraska Biocontainment Unit team solicited existing data on infections in children and transmission phenomena while advising local and state health officials on community-wide mitigation measures to implement in early March. The Singapore NCID team was able to provide particularly valuable information on how the government and community were managing the outbreak given the relative control Singapore had achieved when compared to neighboring countries. Even earlier, as multiple GIDPN members were at the forefront of receiving large groups of individuals repatriated from COVID-affected areas (e.g., cruise ships, medical evacuations), one of the first GIDPN calls during the response centered around the logistics of quarantine, isolation, testing, and identification of positive cases in these cohorts.

Clinically, on a regularly scheduled biweekly call in early spring, the medical director of the Frankfurt HLIU discussed the success the team had with improving blood oxygenation of patients with COVID-19 by proning, including awake proning of non-intubated patients; this directly led to UNMC being an early US adopter of the process. Other clinical discussions that informed local practices included the appropriate testing strategy for diagnosis (i.e., single vs multiple tests); shared early observations of the use of convalescent plasma and its relationship to neutralizing antibody titers and outcomes; and conversations on early ICU admission and elective intubation in well-controlled environments.

A c c e p t e d M a n u s c r i p t 7

During the early phase of the COVID-19 pandemic, many off-label or even unlicensed therapeutic agents were used prior to the availability of clinical trials, including agents such as lopinavir / ritonavir, azithromycin, and hydroxochloroquine. Information on "repurposed" medication was shared among the network members, and there was general concurrence in the group that these agents should be used in the context of randomized controlled trials (RCTs) such as the World Health Organization SOLIDARITY/RECOVERY trial. Group members also agreed that inclusion of patients into RCTs should come at a high priority. As the pandemic progressed, all of the above agents were proven ineffective, validating the group's approach. The one pharmaceutical intervention the group did endorse based on early experience and known side effect profile in critical illness was dexamethasone, a substance that was later shown to be beneficial in more advanced disease stages of COVID-19 [8] .

UNMC and NCID were two of the first research teams to publish evidence supporting aerosol transmission of SARS-COV-2 [9, 10] . During biweekly network calls, prior to study publications, the research teams presented preliminary findings to GIDPN members; these findings, in turn, informed PPE selection and isolation precautions well before national and international guidelines adopted such Global evidence to inform strategies for de-isolation of SARS-CoV-2 positive patients (i.e., time-or test-based) was lacking in the first several months of the pandemic and was a key discussion topic with GIDPN members. A conversation with the NCID team, which released a position statement on the subject in May 2020 [11] , influenced UNMC's decision to move to a time-based de-isolation strategy in early June 2020, which occurred prior to US Centers for Disease Control and Prevention (CDC) recommendations. Conversations also provided advice and experience on how changes to this strategy were communicated and rolled out in other member units. Moreover, the group discussed optimal specimen types and yield according to duration of illness as well as presence or absence of pneumonia that informed diagnostic processes [12] .

The expertise and varying global experiences of GIDPN partners were leveraged during the early months of the COVID-19 pandemic to inform rapid clinical decisions at a time when information was frequently evolving and sufficient evidence on IPC processes, therapeutics, and treatment were absent. The value of such international clinical networking amid a global pandemic of a novel disease to the five GIDPN members cannot be understated. Frank conversations on early clinical and epidemiological characteristics and anecdotal evidence of the success of various therapeutics prior to availability of clinical trials informed clinical teams' decision-making within the local context (e.g., existing resources, surge situation). Member units authored some of the early COVID-19 hallmark studies related to clinical observations of patients, aerosol transmission, and epidemiological investigations, and often the design of these studies was shaped by early discussions within the network [9, 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Sharing of preliminary research findings from these studies, as well as from more informal, quality improvement studies, allowed access to real-time data well before it became available in the scientific and medical communities.

A c c e p t e d M a n u s c r i p t 9 During a pandemic where information and guidance were lacking, the clinical networking facilitated by GIDPN allowed for rapid epidemiologic and clinical decision-making in a local context.

Members benefited from the rapid information exchange which, in many cases, led to local decisions to adopt treatment modalities and implement IPC protocols well before peer institutions or before incorporation of such processes in national guidelines or recommendations. While this exchange had clear value for member institutions, a global gap in practice remains in effectively and rapidly disseminating the expertise and lessons learned generated at these HLIUs to the broader network of healthcare facilities that will care for most cases during a pandemic. Although many findings The global infrastructure of high-level isolation care has drastically changed in the last decade: the once infrequent, sporadic cases of HCIDs being treated in these specialized units has become an increasingly frequent occurrence, and many HLIUs have been established in the last A c c e p t e d M a n u s c r i p t 10 decade in anticipation of emerging infectious disease events to come. To date, as an international network of HLIUs, GIDPN has been leveraged to enhance treatment and management of patients with HCIDs through best practice and information-sharing and served as an invaluable resource during the COVID-19 pandemic. However, the COVID-19 pandemic also highlighted the role HLIUs are likely to play in pandemics of novel or reemerging special pathogens that outstrip the national and international capacity of HLIUs. The units have clear value for early stages of such pandemics, but surge capacity must be addressed. We are at an optimal point in time, as the continued vulnerabilities in global health security are once again highlighted through the COVID-19 pandemic, to plan for these types of pandemics and how best to leverage HLIU expertise, experience, and national roles to increase HCID preparedness and capacity for the future. The value of such a network was highlighted during the pandemic; GIDPN and similar networks will become increasingly integral in enhancing local, national, and global preparedness for and response to future epidemics/pandemics. 

Trends in COVID-19 Risk-Adjusted Mortality Rates

Emerging Infectious Diseases: Epidemiological Perspective

Infection Rates and Risk Factors for Infection Among Health Workers During Ebola and Marburg Virus Outbreaks: A Systematic Review

Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: a cross-sectional study

Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto

Severe acute respiratory syndrome: providing care in the face of uncertainty

Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases

Solidarity study group

Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care

Detection of air and surface contamination by SARS-CoV-2 in hospital rooms of infected patients

The Effect of Sample Site, Illness Duration, and the Presence of Pneumonia on the Detection of SARS-CoV-2 by Real-time Reverse Transcription PCR, Open Forum Infectious Diseases

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Epidemiological and Clinical Predictors of COVID-19

Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China

Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod

Clinical progression of patients with COVID-19 in Shanghai

Clinical observation and management of COVID-19 patients

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

COVID-19 with Different Severities: A Multicenter Study of Clinical Features

Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

A minimal outcome measure set for COVID-19 clinical research

We would like to thank the following individuals for their involvement in GIDPN and discussions 

No funding source.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t